StockData
Gossamer Bio, Inc. logo

Gossamer Bio, Inc. (GOSS) stock

GOSSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 1/30
$11.04+0.06 (+0.55%)

Close on Nov 17, 2026Market cap $5.40BP/E –Yield –

Gossamer Bio operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Gossamer Bio's operating cash flow for the twelve months ending Jun 30, 2026 was -$162.63M. For fiscal 2025 it was -$171.27M. The highest annual figure on record is -$3.47M in fiscal 2024.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$171.27M–
FY2024Dec 31, 2024-$3.47M–
FY2023Dec 31, 2023-$159.16M–
FY2022Dec 31, 2022-$187.03M–
FY2021Dec 31, 2021-$188.89M–
FY2020Dec 31, 2020-$176.36M–
FY2019Dec 31, 2019-$144.83M–
FY2018Dec 31, 2018-$51.04M–
FY2017Dec 31, 2017-$5.75M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$39.42M–
Q1 FY2026Mar 31, 2026-$38.72M–
Q4 FY2025Dec 31, 2025-$48.31M–
Q3 FY2025Sep 30, 2025-$36.17M–
Q2 FY2025Jun 30, 2025-$47.06M-140.4%
Q1 FY2025Mar 31, 2025-$39.72M–
Q4 FY2024Dec 31, 2024-$35.48M–
Q3 FY2024Sep 30, 2024-$32.03M–
Q2 FY2024Jun 30, 2024$116.35M–
Q1 FY2024Mar 31, 2024-$52.30M–
Q4 FY2023Dec 31, 2023-$33.42M–
Q3 FY2023Sep 30, 2023-$34.49M–
Q2 FY2023Jun 30, 2023-$38.25M–
Q1 FY2023Mar 31, 2023-$52.99M–
Q4 FY2022Dec 31, 2022-$47.73M–
Q3 FY2022Sep 30, 2022-$37.00M–
Q2 FY2022Jun 30, 2022-$48.82M–
Q1 FY2022Mar 31, 2022-$53.48M–
Q4 FY2021Dec 31, 2021-$40.51M–
Q3 FY2021Sep 30, 2021-$42.04M–
Q2 FY2021Jun 30, 2021-$47.45M–
Q1 FY2021Mar 31, 2021-$58.90M–
Q4 FY2020Dec 31, 2020-$36.74M–
Q3 FY2020Sep 30, 2020-$44.93M–
Q2 FY2020Jun 30, 2020-$42.40M–
Q1 FY2020Mar 31, 2020-$52.30M–
Q4 FY2019Dec 31, 2019-$44.14M–
Q3 FY2019Sep 30, 2019-$36.11M–
Q2 FY2019Jun 30, 2019-$36.81M–
Q1 FY2019Mar 31, 2019-$27.77M–
Q4 FY2018Dec 31, 2018-$25.02M–
Q3 FY2018Sep 30, 2018-$15.52M–
Q2 FY2018Jun 30, 2018-$6.80M–
Q1 FY2018Mar 31, 2018-$3.71M–

More Gossamer Bio figures

See a number that looks wrong?